Workflow
仁和药业跌2.00%,成交额1.57亿元,主力资金净流出2259.23万元

Core Viewpoint - Renhe Pharmaceutical's stock price has shown fluctuations, with a recent decline of 2.00% on September 19, 2023, and a total market capitalization of 8.918 billion yuan [1] Group 1: Stock Performance - Year-to-date, Renhe Pharmaceutical's stock price has increased by 13.55%, but it has seen a decline of 0.62% over the last five trading days and 4.21% over the last twenty days [2] - The stock has experienced a 17.53% increase over the last sixty days [2] Group 2: Financial Performance - For the first half of 2025, Renhe Pharmaceutical reported a revenue of 1.975 billion yuan, a year-on-year decrease of 16.46%, and a net profit attributable to shareholders of 290 million yuan, down 13.87% year-on-year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.962 billion yuan, with 770 million yuan distributed over the last three years [3] Group 3: Shareholder Information - As of June 30, 2025, the number of shareholders for Renhe Pharmaceutical was 104,400, a decrease of 2.76% from the previous period [2] - The top ten circulating shareholders include Hong Kong Central Clearing Limited and Southern CSI 1000 ETF, with both increasing their holdings compared to the previous period [3]